Benign Nail Condition Linked to Rare Syndrome that Greatly Increases Cancer Risk

NIH researchers suggest conducting nail evaluation of affected patients and at-risk family members

Scientists at the National Institutes of Health (NIH) have discovered that the presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (e.g.,Read full story

Scientists Unravel Genetic Basis for Neurodegenerative Disorders That Affect Vision

NIH-led findings point to a biomarker for rare disorders associated with the gene PNPLA6.

Led by researchers at the National Institutes of Health (NIH), a team of scientists has uncovered the complex molecular mechanisms underlying neurodegenerative disorders linked to the gene PNPLA6, which encompass a range of conditions affecting mobility, vision, and hormonal regulation.Read full story

Over 115 Million Pills Containing Illicit Fentanyl Seized by Law Enforcement in 2023

NIH-supported study highlights increasingly dangerous illicit drug supply, risk of pills not coming from a pharmacy.

Law enforcement seizures of illicit fentanyl increased dramatically in number and size between 2017 to 2023 in the U.S., especially in pill form, according to a new study funded by the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA).Read full story

Nurses Month Celebrations

During the month of May, KCH recognizes the efforts and time dedicated by its nursing staff.

They know firsthand what their patients need to be safe and comfortable and how to improve their quality of care while showing compassion and professionalism.Read full story

Faster Approach for Starting Extended-Release Naltrexone to Treat Opioid Use Disorder Shown Effective

NIH-supported clinical trial addresses important barrier to opioid use disorder treatment.

Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking treatment is more effective than the standard treatment method of starting within 10-15 days, but requires closer medical supervision, according to results from a clinical trial supported by the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA).Read full story

NIH to Open Long COVID Clinical Trials to Study Sleep Disturbances, Exercise Intolerance, and Post Exertional Malaise

Part of the NIH RECOVER Initiative, trials will test four treatments.


People 18 years of age and older who are interested in learning more about these trials can visit or and search identifiers NCT06404047NCT06404060NCT06404073NCT06404086NCT06404099NCT06404112.Read full story